The Role of Hyaluronan and CD44 in the Pathogenesis of Lupus Nephritis
Autoimmune Diseases · 2012
DOI: 10.1155/2012/207190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Autoimmune Diseases, 2012. Verfasst von Susan Yung und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Hong Kong, Room 302 New Clinical Building, Queen Mary Hospital, Pokfulam, Hong Kong. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is a prototype autoimmune disease that affects multiorgan systems. Lupus nephritis is one of the most severe manifestations of SLE whereby immune-mediated inflammation can lead to permanent damage within the glomerular, tubulo-interstitial, and vascular compartments of the kidney, resulting in acute or chronic renal failure. The mechanisms that regulate host inflammatory responses and tissue injury are incompletely understood. Accumulating evidence suggests that hyaluronan and its interaction with its cell surface receptor CD44 plays an important role in mediating pathogenic mechanisms in SLE. This paper discusses the putative mechanisms through which hyaluronan and CD44 contribute to the pathogenesis of SLE, with particular emphasis on lupus nephritis.
Autor:innen und Institutionen
- Department of Medicine, University of Hong Kong, Room 302 New Clinical Building, Queen Mary Hospital, Pokfulam, Hong Kong.
Zitieren
APA
Yung, S., & Chan, T. M. (2012). The Role of Hyaluronan and CD44 in the Pathogenesis of Lupus Nephritis. Autoimmune Diseases. https://doi.org/10.1155/2012/207190
Vancouver
Yung S, Chan TM. The Role of Hyaluronan and CD44 in the Pathogenesis of Lupus Nephritis. Autoimmune Diseases. 2012. doi:10.1155/2012/207190
BibTeX
@article{Yung2012,
author = {Yung, Susan and Chan, Tak Mao},
title = {The Role of Hyaluronan and CD44 in the Pathogenesis of Lupus Nephritis},
journal = {Autoimmune Diseases},
year = {2012},
doi = {10.1155/2012/207190}
}
EUVIMED